These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22624710)

  • 1. Opening a new GATAway for treating KRAS-driven lung tumors.
    Barbacid M
    Cancer Cell; 2012 May; 21(5):598-600. PubMed ID: 22624710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cationic lipid-assisted polymeric nanoparticle mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma.
    Shen S; Mao CQ; Yang XZ; Du XJ; Liu Y; Zhu YH; Wang J
    Mol Pharm; 2014 Aug; 11(8):2612-22. PubMed ID: 24521262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GATA2 is epigenetically repressed in human and mouse lung tumors and is not requisite for survival of KRAS mutant lung cancer.
    Tessema M; Yingling CM; Snider AM; Do K; Juri DE; Picchi MA; Zhang X; Liu Y; Leng S; Tellez CS; Belinsky SA
    J Thorac Oncol; 2014 Jun; 9(6):784-93. PubMed ID: 24807155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.
    Kumar MS; Hancock DC; Molina-Arcas M; Steckel M; East P; Diefenbacher M; Armenteros-Monterroso E; Lassailly F; Matthews N; Nye E; Stamp G; Behrens A; Downward J
    Cell; 2012 Apr; 149(3):642-55. PubMed ID: 22541434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
    Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
    Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.
    Steckel M; Molina-Arcas M; Weigelt B; Marani M; Warne PH; Kuznetsov H; Kelly G; Saunders B; Howell M; Downward J; Hancock DC
    Cell Res; 2012 Aug; 22(8):1227-45. PubMed ID: 22613949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GATA binding protein 2 overexpression is associated with poor prognosis in KRAS mutant colorectal cancer.
    Xu K; Wang J; Gao J; Di J; Jiang B; Chen L; Wang Z; Wang A; Wu F; Wu W; Shen L; Su X
    Oncol Rep; 2016 Sep; 36(3):1672-8. PubMed ID: 27460045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.
    Wood K; Hensing T; Malik R; Salgia R
    JAMA Oncol; 2016 Jun; 2(6):805-12. PubMed ID: 27100819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery.
    Mao CQ; Xiong MH; Liu Y; Shen S; Du XJ; Yang XZ; Dou S; Zhang PZ; Wang J
    Mol Ther; 2014 May; 22(5):964-73. PubMed ID: 24496383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer.
    Burns TF; Dobromilskaya I; Murphy SC; Gajula RP; Thiyagarajan S; Chatley SN; Aziz K; Cho YJ; Tran PT; Rudin CM
    Mol Cancer Res; 2013 Apr; 11(4):329-38. PubMed ID: 23364532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PKC
    Garg R; Cooke M; Benavides F; Abba MC; Cicchini M; Feldser DM; Kazanietz MG
    Cancer Res; 2020 Dec; 80(23):5166-5173. PubMed ID: 32994205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer.
    Yang Z; Liang SQ; Zhao L; Yang H; Marti TM; Hegedüs B; Gao Y; Zheng B; Chen C; Wang W; Dorn P; Kocher GJ; Schmid RA; Peng RW
    J Exp Clin Cancer Res; 2022 Jan; 41(1):25. PubMed ID: 35039048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IKK is a therapeutic target in KRAS-Induced lung cancer with disrupted p53 activity.
    Bassères DS; Ebbs A; Cogswell PC; Baldwin AS
    Genes Cancer; 2014 Apr; 5(1-2):41-55. PubMed ID: 24955217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis.
    Mou H; Moore J; Malonia SK; Li Y; Ozata DM; Hough S; Song CQ; Smith JL; Fischer A; Weng Z; Green MR; Xue W
    Proc Natl Acad Sci U S A; 2017 Apr; 114(14):3648-3653. PubMed ID: 28320962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.
    Acquaviva J; Smith DL; Sang J; Friedland JC; He S; Sequeira M; Zhang C; Wada Y; Proia DA
    Mol Cancer Ther; 2012 Dec; 11(12):2633-43. PubMed ID: 23012248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
    Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK
    Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.
    Carneiro-Lobo TC; Scalabrini LC; Magalhães LDS; Cardeal LB; Rodrigues FS; Dos Santos EO; Baldwin AS; Levantini E; Giordano RJ; Bassères DS
    Lung Cancer; 2019 Apr; 130():169-178. PubMed ID: 30885340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis.
    Bogucka K; Marini F; Rosigkeit S; Schloeder J; Jonuleit H; David K; Schlackow M; Rajalingam K
    Cancer Gene Ther; 2021 May; 28(5):359-374. PubMed ID: 33070159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways.
    Patel A; Burton DG; Halvorsen K; Balkan W; Reiner T; Perez-Stable C; Cohen A; Munoz A; Giribaldi MG; Singh S; Robbins DJ; Nguyen DM; Rai P
    Oncogene; 2015 May; 34(20):2586-96. PubMed ID: 25023700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.
    Barbie DA; Tamayo P; Boehm JS; Kim SY; Moody SE; Dunn IF; Schinzel AC; Sandy P; Meylan E; Scholl C; Fröhling S; Chan EM; Sos ML; Michel K; Mermel C; Silver SJ; Weir BA; Reiling JH; Sheng Q; Gupta PB; Wadlow RC; Le H; Hoersch S; Wittner BS; Ramaswamy S; Livingston DM; Sabatini DM; Meyerson M; Thomas RK; Lander ES; Mesirov JP; Root DE; Gilliland DG; Jacks T; Hahn WC
    Nature; 2009 Nov; 462(7269):108-12. PubMed ID: 19847166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.